Cargando…

Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy

OBJECTIVE: It has been reported that anti-mitochondrial antibodies (AMAs) recognize mitochondrial antigens and are associated with some diseases involving multiple organs, such as primary biliary cholangitis, Sjögren syndrome, Hashimoto's thyroiditis, systemic sclerosis, interstitial pneumoniae...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokokawa, Tetsuro, Yoshihisa, Akiomi, Misaka, Tomofumi, Sato, Takamasa, Kaneshiro, Takashi, Oikawa, Masayoshi, Kobayashi, Atsushi, Yamaki, Takayoshi, Kunii, Hiroyuki, Takeishi, Yasuchika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872813/
https://www.ncbi.nlm.nih.gov/pubmed/33456024
http://dx.doi.org/10.2169/internalmedicine.5422-20
_version_ 1783649259409637376
author Yokokawa, Tetsuro
Yoshihisa, Akiomi
Misaka, Tomofumi
Sato, Takamasa
Kaneshiro, Takashi
Oikawa, Masayoshi
Kobayashi, Atsushi
Yamaki, Takayoshi
Kunii, Hiroyuki
Takeishi, Yasuchika
author_facet Yokokawa, Tetsuro
Yoshihisa, Akiomi
Misaka, Tomofumi
Sato, Takamasa
Kaneshiro, Takashi
Oikawa, Masayoshi
Kobayashi, Atsushi
Yamaki, Takayoshi
Kunii, Hiroyuki
Takeishi, Yasuchika
author_sort Yokokawa, Tetsuro
collection PubMed
description OBJECTIVE: It has been reported that anti-mitochondrial antibodies (AMAs) recognize mitochondrial antigens and are associated with some diseases involving multiple organs, such as primary biliary cholangitis, Sjögren syndrome, Hashimoto's thyroiditis, systemic sclerosis, interstitial pneumoniae, dilated cardiomyopathy, and tubulointerstitial nephritis. In the current study, we examined the prevalence of AMAs in patients with dilated cardiomyopathy (DCM) and their clinical characteristics. METHODS: We enrolled 270 patients with DCM. We measured serum AMAs and analyzed the associated factors. Out of the 270 patients, positive AMAs were detected in 3 patients (1.1%; mean age, 68 years old; 2 men). These three patients had a significantly higher prevalence of primary biliary cholangitis and myopathy and levels of alanine alkaline phosphatase than those who were negative for said antibodies. There were no significant differences in the levels of B-type natriuretic peptide, aspartate transaminase, and left ventricular ejection fraction between these groups of patients. During the follow-up period, two of the three patients died due to respiratory failure. The other patient survived but experienced type II respiratory failure. CONCLUSION: The prevalence of AMAs in 270 DCM patients was only 1.1%, and these patients suffered from respiratory failure.
format Online
Article
Text
id pubmed-7872813
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-78728132021-02-17 Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy Yokokawa, Tetsuro Yoshihisa, Akiomi Misaka, Tomofumi Sato, Takamasa Kaneshiro, Takashi Oikawa, Masayoshi Kobayashi, Atsushi Yamaki, Takayoshi Kunii, Hiroyuki Takeishi, Yasuchika Intern Med Original Article OBJECTIVE: It has been reported that anti-mitochondrial antibodies (AMAs) recognize mitochondrial antigens and are associated with some diseases involving multiple organs, such as primary biliary cholangitis, Sjögren syndrome, Hashimoto's thyroiditis, systemic sclerosis, interstitial pneumoniae, dilated cardiomyopathy, and tubulointerstitial nephritis. In the current study, we examined the prevalence of AMAs in patients with dilated cardiomyopathy (DCM) and their clinical characteristics. METHODS: We enrolled 270 patients with DCM. We measured serum AMAs and analyzed the associated factors. Out of the 270 patients, positive AMAs were detected in 3 patients (1.1%; mean age, 68 years old; 2 men). These three patients had a significantly higher prevalence of primary biliary cholangitis and myopathy and levels of alanine alkaline phosphatase than those who were negative for said antibodies. There were no significant differences in the levels of B-type natriuretic peptide, aspartate transaminase, and left ventricular ejection fraction between these groups of patients. During the follow-up period, two of the three patients died due to respiratory failure. The other patient survived but experienced type II respiratory failure. CONCLUSION: The prevalence of AMAs in 270 DCM patients was only 1.1%, and these patients suffered from respiratory failure. The Japanese Society of Internal Medicine 2021-01-15 2021-01-15 /pmc/articles/PMC7872813/ /pubmed/33456024 http://dx.doi.org/10.2169/internalmedicine.5422-20 Text en Copyright © 2021 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Yokokawa, Tetsuro
Yoshihisa, Akiomi
Misaka, Tomofumi
Sato, Takamasa
Kaneshiro, Takashi
Oikawa, Masayoshi
Kobayashi, Atsushi
Yamaki, Takayoshi
Kunii, Hiroyuki
Takeishi, Yasuchika
Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy
title Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy
title_full Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy
title_fullStr Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy
title_full_unstemmed Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy
title_short Anti-mitochondrial Antibodies in Patients with Dilated Cardiomyopathy
title_sort anti-mitochondrial antibodies in patients with dilated cardiomyopathy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872813/
https://www.ncbi.nlm.nih.gov/pubmed/33456024
http://dx.doi.org/10.2169/internalmedicine.5422-20
work_keys_str_mv AT yokokawatetsuro antimitochondrialantibodiesinpatientswithdilatedcardiomyopathy
AT yoshihisaakiomi antimitochondrialantibodiesinpatientswithdilatedcardiomyopathy
AT misakatomofumi antimitochondrialantibodiesinpatientswithdilatedcardiomyopathy
AT satotakamasa antimitochondrialantibodiesinpatientswithdilatedcardiomyopathy
AT kaneshirotakashi antimitochondrialantibodiesinpatientswithdilatedcardiomyopathy
AT oikawamasayoshi antimitochondrialantibodiesinpatientswithdilatedcardiomyopathy
AT kobayashiatsushi antimitochondrialantibodiesinpatientswithdilatedcardiomyopathy
AT yamakitakayoshi antimitochondrialantibodiesinpatientswithdilatedcardiomyopathy
AT kuniihiroyuki antimitochondrialantibodiesinpatientswithdilatedcardiomyopathy
AT takeishiyasuchika antimitochondrialantibodiesinpatientswithdilatedcardiomyopathy